Home › Compare › UMEWF vs ABBV
UMEWF yields 487.80% · ABBV yields 3.06%● Live data
📍 UMEWF pulled ahead of the other in Year 1
Combined, UMEWF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of UMEWF + ABBV for your $10,000?
UMeWorld Limited, together with its subsidiaries, operates as an educational technology company with a focus on the K-12 education market in China. It offers UMFun, a cloud-based assessment and learning analytics platform that analyzes and adapts to a student's performance and personalizes the delivery of proprietary educational items in accordance with the student's learning needs. The company's platform provides standards-based instruction, practice, assessments, and productivity tools that enhance the performance of educators and students. Its products also enable educators to track student performance in real-time to address individual student learning gaps while allowing administrators to monitor student progress and measure teacher effectiveness. It serves schools, teachers, students, and parents through online and mobile platforms. The company was formerly known as AlphaRx, Inc. and changed its name to UMeWorld Limited in March 2013. UMeWorld Limited was incorporated in 1997 and is based in Causeway Bay, Hong Kong.
Full UMEWF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.